UNCY INVESTOR REMINDER: Unicycive Therapeutics, Inc. Investors Have Until November 2, 2026 To Contact Kirby McInerney LLP to Seek Lead Plaintiff Role

NEW YORK--(BUSINESS WIRE)--If you have suffered a loss on your Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY) investment, contact Lauren Molinaro of Kirby McInerney LLP by email at [e-mail], or fill out the contact form below to discuss your rights or interests in the securities fraud class action lawsuit at no cost.

Investors have until November 2, 2026 to ask the Court to appoint them as lead plaintiff. Courts do not consider applications filed after this deadline. The lead plaintiff oversees the litigation on behalf of the class and may influence key decisions, including litigation strategy and settlement. Courts regularly appoint individual investors as lead plaintiffs, not only institutions. Learn more about the lead plaintiff process and eligibility requirements here.

[CONTACT THE FIRM IF YOU SUFFERED A LOSS]

What Is The Lawsuit About?

The lawsuit has been filed on behalf of investors who purchased securities during the period of December 29, 2025 through June 29, 2026, inclusive (“the Class Period”). The lawsuit alleges that Unicycive made false and/or misleading statements and failed to disclose to investors that: (i) the Company had not inspected its third-party manufacturing vendor’s facility or otherwise audited the facility’s compliance with current good manufacturing practices; (ii) as a result, the Company lacked a reasonable basis to believe that the vendor had resolved the FDA’s cited deficiencies; (iii) there was an undisclosed risk that the FDA would require additional information about the vendor’s facility’s manufacturing practices; and (iv) as a result of the foregoing, the regulatory approval of oxylanthanum carbonate (“OLC”), a kidney disease therapy, was reasonably likely to be delayed.

On June 30, 2026, Unicycive disclosed that the FDA had issued a second Complete Response Letter regarding the Company’s resubmitted New Drug Application for OLC, identifying the “same third-party manufacturing deficiencies that were identified in the previous CRL issued in June 2025.” On this news, Unicycive’s stock price fell $3.01 or 39.1%, to close at $4.69 per share on June 30. 2026.

[CLICK HERE TO LEARN MORE ABOUT THE CLASS ACTION]

What Should I Do?

If you purchased or otherwise acquired Unicycive securities, have information, or would like to learn more about this investigation, please contact Lauren Molinaro of Kirby McInerney LLP by email at [e-mail], or fill out the contact form below, to discuss your rights or interests with respect to these matters at no cost.

[WHAT IS A SECURITIES CLASS ACTION?]

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.